Equality impact assessment – Scoping

MTA Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85)

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Consultees noted that Jehovah’s witnesses are sometimes unwilling to be treated with intravenous human immunoglobulin.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Consideration should be given to the treatment options available for people who are unwilling to receive human blood products, to ensure that any recommendations do not directly or indirectly discriminate on the basis of religion. The final scope includes a number of interventions that are not based on human blood products.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes are needed.
4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

The patient organisation Hospital Information Services (Jehovah’s Witnesses) has been added to the matrix.

Approved by Associate Director (name): Helen Knight

Date: 01/07/2014